Table 1.
Main clinical characteristics of PAH patients and controls
| PAH patients (n = 34) | Controls (n = 27) | P-value | |
| Age (years) | 61.8 ± 15.7 | 41.7 ± 15.7 | <0.001 |
| Gender (M/F) | 13/21 | 15/12 | 0.18 |
| BMI (kg/m2) | 1.70 ± 0.18 | 1.83 ± 0.20 | 0.74 |
| WHO class (I/II/III/IV/unknown) | 2/21/9/0/2 | – | – |
| BNP (n, pg/mL)a | 150.70 ± 102.82 | – | – |
| NT-proBNP (n, pg/mL)b | 904.30 ± 1596.53 | – | – |
| 6MWT (m)c | 406.25 ± 118.74 | – | – |
| CI (L/min/m2)d | 2.93 ± 1.04 | – | – |
| PAPm (mmHg)d | 39.20 ± 12.76 | – | – |
| PAWP (mmHg)d | 8.87 ± 2.58 | – | – |
| PVR (UW)d | 7.60 ± 3.67 | – | – |
| PAH-specific monotherapy/dual therapy/triple therapy/none (n, %)e | 3 (9%)/23 (70%)/4 (12%)/3 (9%) | – | – |
6MWT, 6-min walking test; BMI, body mass index; BNP, B-type natriuretic peptide; CI, cardiac index; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAH, pulmonary artery hypertension; PAPm, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; WHO, World Health Organization.
a
Data are available for 13 patients only.
b
Data are available for 18 patients only.
c
Data are available for 32 patients only.
d
Data are available for 31 patients only.
e
Data are available for 33 patients only; patients with no therapy were those receiving calcium-antagonists. Patients with infusion devices were not included.